Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US-2015344544-A1 · Dec 3, 2015 · US
Anti-influenza antibody
US2016376347A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016376347-A1 |
| Application number | US-201314651043-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 11, 2013 |
| Priority date | Dec 11, 2012 |
| Publication date | Dec 29, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to an antibody that confers protection against influenza virus infection. More specifically, it relates to an anti-neuraminidase antibody, protecting against highly pathogenic H5N1 influenza strains. The invention relates further to the use of the antibody for prophylactic and/or therapeutic treatment of influenzavirusinfections, and to a pharmaceutical composition comprising the antibody.
First claim
Opening claim text (preview).
1 . A VHH specifically binding influenza neuraminidase. 2 . The VHH according to claim 1 , comprising a CDR1 loop sequence selected from the group consisting of SEQ ID N° 1 and SEQ ID N° 2, a CDR2 loop sequence selected from the group consisting of SEQ ID N° 3 and SEQ ID N° 4 and a CDR3 loop sequence consisting of SEQ ID N° 5 and SEQ ID N° 6. 3 . An influenza neuraminidase binding construct comprising a VHH according to claim 1 . 4 . The neuraminidase binding construct according to claim 3 , wherein said construct is bivalent. 5 . The neuraminidase binding construct according to claim 4 , wherein said VHH is fused to an Fc tail. 6 . The neuraminidase binding construct according to claim 4 , wherein said VHHs are linked by an IgG2c hinge. 7 . The neuraminidase binding construct according to claim 5 , wherein said construct comprises a sequence selected from the group consisting of SEQ ID N° 7, SEQ ID N° 8, SEQ ID N° 9 and SEQ ID N° 10. 8 . A method of treatment of an influenza infection, the method comprising administering to a subject in need thereof an influenza neuraminidase binding construct according to claim 3 . 9 . A pharmaceutical composition comprising an influenza binding construct according to claim 3 . 10 . An influenza neuraminidase binding construct comprising a VHH according to claim 2 . 11 . The neuraminidase binding construct according to claim 10 , wherein said construct is bivalent. 12 . The neuraminidase binding construct according to claim 11 , wherein said VHH is fused to an Fc tail. 13 . The neuraminidase binding construct according to claim 11 , wherein said VHHs are linked by an IgG2c hinge. 14 . The neuraminidase binding construct according to claim 6 , wherein said construct comprises a sequence selected from the group consisting of SEQ ID N° 7, SEQ ID N° 8, SEQ ID N° 9 and SEQ ID N° 10. 15 . A pharmaceutical composition comprising an influenza binding construct according to claim 4 . 16 . A pharmaceutical composition comprising an influenza binding construct according to claim 5 . 17 . A pharmaceutical composition comprising an influenza binding construct according to claim 6 . 18 . A pharmaceutical composition comprising an influenza binding construct according to claim 7 . 19 . A pharmaceutical composition comprising an influenza binding construct according to claim 10 . 20 . A method of treatment of an influenza infection, the method comprising administering to a subject in need thereof an influenza neuraminidase binding construct according to claim 7 .
Assignees
Inventors
Classifications
isolated from plants · CPC title
Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody® · CPC title
Valency · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
comprising antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016376347A1 cover?
- The present invention relates to an antibody that confers protection against influenza virus infection. More specifically, it relates to an anti-neuraminidase antibody, protecting against highly pathogenic H5N1 influenza strains. The invention relates further to the use of the antibody for prophylactic and/or therapeutic treatment of influenzavirusinfections, and to a pharmaceutical composition…
- Who is the assignee on this patent?
- Vib Vzw, Univ Gent, Vrije Universeteit Brussel, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/108. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Dec 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).